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Abstract
The complement inhibitor eculizumab is a humanised monoclonal antibody
against C5. It was developed to specifically target cleavage of C5 thus preventing
release of C5a and activation of the terminal pathway. Paroxysmal nocturnal
haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) are two
diseases with distinctly different underlying molecular mechanisms. In PNH, progeny
of haematopoietic stem cells that harbour somatic mutations lead to a population of
peripheral blood cells that are deficient in complement regulators resulting in
haemolysis and thrombosis. In aHUS, germline mutations in complement proteins or
their regulators fail to protect the glomerular endothelium from complement activation
resulting in thrombotic microangiopathy and renal failure. Critical to the development
of either disease is activation of the terminal complement pathway. Understanding
this step has led to the study of eculizumab as a treatment for these diseases. In
clinical trials, eculizumab is proven to be effective and safe in PNH and aHUS.
Abbreviations
AE Adverse events
aHUS Atypical haemolytic uraemic syndrome
AP Alternative pathway
C3bB Proconvertase
C3bBb C3 convertase
CKD Chronic kidney disease
CP Classical pathway
CR1 Complement receptor 1
DAF, CD55 Decay acceleration factor
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DGKε diacylglycerol kinase ε 
FB Complement factor B
FD Complement factor D
FH Complement factor H
FI Complement factor I
GAG Glycosaminoglycans
GPI Glycosyl phosphatidylinositol
GPI-AP Glycosyl phosphatidylinositol anchoring protein
IgG Immunoglobulin class G
LDH Lactate dehydrogenase
LP Lectin pathway
MAC, C5b-9 Membrane attack complex
MCP, CD46 Membrane cofactor protein
NO Nitric oxide
PEX Plasma exchange
PIGA Phosphatidylinositol glycan class A
PNH Paroxysmal nocturnal haemoglobinuria
SNP Single nucleotide polymorphism
Stx Shiga-toxin
TMA Thrombotic microangiopathy
TTP Thrombotic thrombocytopaenia
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Introduction
Eculizumab remains the first and only inhibitor of the complement system used
in clinical practice. Specifically, it targets the terminal complement pathway and
leaves the proximal complement pathways intact. It was approved by the United
States Food and Drug Administration and the European Medicines Agency in 2007
for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and in 2011 for the
treatment of atypical haemolytic uraemic syndrome (aHUS). This review discusses
the current use and potential limitations of eculizumab as a therapeutic agent.
The complement system
The complement system comprises a network of proteins that work in concert
as part of the innate immune system and has been extensively reviewed (1). Their
role in orchestrating the immune response extends beyond the concept of ‘first line
of defence’. It bridges innate and adaptive immunity (2) and plays a key role in
removal of immune complexes and injured cells and tissues (3).
Briefly, and summarised in figure 1, complement can be activated via the
classical pathway (CP) through antibody-antigen interactions and lectin pathway (LP)
through pattern recognition molecules expressed on the sugar coating of bacteria.
These lead to the formation of the C3 convertase of the classical pathway leading to
cleavage of C3 into C3a and C3b. Complement also activates via the alternative
pathway (AP) through hydrolysis of C3 into C3H20 by a process known as ‘tickover’.
This binds complement factor B (FB) to form C3H2OB which is then converted to
C3H2OBb by the action of complement factor D (FD). This initial convertase can also
cleave C3 into C3a and C3b.
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C3b from any activation pathway then enters the amplification loop of the AP by
binding FB to form a proconvertase (C3bB). In the presence of FD, C3bB is cleaved
to form the C3 convertase of the alternative pathway (C3bBb) which again cleaves
C3. C3a is released in its effector role as an anaphylatoxin. C3b binds FB to feed
back into a positive amplification loop resulting in the massive generation of C3b for
opsonisation.
As the density of C3b on cell surfaces increases, convertases with an extra
C3b subunit form and change specificity from C3 to C5 allowing cleavage of C5. In
this terminal pathway, cleavage of C5 leads to the production of C5a and C5b. C5a
instigates inflammation whilst C5b binds C6, C7, C8 to form C5b-8 as part of the lytic
pathway before a final protein C9 completes the formation of the membrane attack
complex (MAC, C5b-9). In total 80-90% of complement activation results from the
amplification loop of AP regardless of the initial mechanism of complement activation
(4).
Given that the AP is spontaneously active, there are complement regulatory
proteins to prevent bystander complement activation and amplification upon host
cells and surfaces. These are found in the circulation and on cell membranes. They
have several functions and are described below. Acceleration of natural decay of
C3bBb (decay acceleration) by complement factor H (FH), decay acceleration factor
(DAF, CD55) and complement receptor 1 (CR1); co-factor activity to allow the
complement factor I (FI) mediated cleavage of C3b into iC3b by FH, CR1 and
membrane co-factor protein (MCP, CD46) and subsequent degradation of iC3b into
C3dg by CR1. In the terminal lytic pathway, the complement regulator CD59, can
block C9 binding to C5b-8 thus preventing the formation of MAC.
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Loss of complement regulation resulting in the inability of complement to
protect host tissue from complement activation has underpinned the pathogenic
mechanism in several diseases including PNH (5) and aHUS (6) (Table 1). These
abnormalities of complement regulation include somatic mutations in haematopoietic
stem cells in PNH and germline mutations in complement genes in aHUS and are
described in more detail later. Through an understanding of these pathogenic
mechanisms, including the importance of the terminal pathway common to both PNH
and aHUS, there have been benefits from the use of the complement inhibitor
eculizumab.
Eculizumab
Development of an anti-C5 antibody began by screening murine monoclonal
immunoglobulin (IgG) that bound to human C5 for the capability to block C5a
generation and complement mediated cell lysis via MAC (7). To reduce
immunogenicity of murine IgG, the antibody was humanised by cloning the variable
regions into human germline heavy-chain and light chain (8). Human IgG activates
complement and has a pro-inflammatory effect upon binding to its target – to
minimize this, the hybrid region utilises the desirable properties both of IgG2, which
fails to bind Fc receptors (9), and IgG4, which does not activate complement to
reduce the pro-inflammatory potential of the antibody (10). This final recombinant
antibody to C5 is now known as eculizumab and retains the ability to block C5a
generation and cell lysis (8).
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Preclinical and early clinical development
Eculizumab is species specific and not effective in murine models. Therefore in
early animal testing, a surrogate mouse anti-C5 antibody was used to study the
effects of MAC inhibition in murine models of both collagen-induced arthritis (11) and
lupus-like autoimmune disease in NZB/WF1 mice (12). The results provided safety
and efficacy data that supported the feasibility of using an antibody therapeutically
for sustained blockade of C5.
Initial clinical development
Initial phase 1 studies in both systemic lupus erythematosis (13) and
rheumatoid arthritis (14, 15) showed that a dose of 8mg/kg blocked complement for
7-14 days. In the small numbers of patients studied, there was a trend towards
clinical improvement. There was no dose dependent trend in adverse effects.
Subsequently, complete blockade of the terminal pathway of complement was
demonstrated in vivo with serum concentrations above 35 μg/mL (16). 
Eculizumab and risk of meningococcal infection
Patients with deficiency of terminal pathway components including C5 strongly
associate with infections with encapsulated organisms including Neisseria
meningitides (17). Therefore all patients receiving eculizumab should receive
vaccination against all known strains. If eculizumab needs to be commenced within
14 days of vaccination, additional prophylactic antibiotics should be given. Until
recently, vaccination was not available for Neisseria meningitides serotype B, the
most common strain in Europe. Many centres currently recommend prophylactic
antibiotics for the duration of eculizumab therapy.
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Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal nocturnal haemoglobinuria is a rare haemolytic anaemia first
described in 1882 (18). Due to intravascular haemolysis, the appearance of
haemoglobin in the urine gives rise to its current name, although this observation is a
presenting feature in only 26% of patients (19, 20). The first diagnostic test for PNH
was demonstrated in the original ‘acidfied serum assay’ or Ham test (21) and the
underlying basis that complement is important in haemolysis was shown in 1954 (22).
The additional disease associations of thrombosis, muscle dystonias, chronic kidney
disease and bone marrow failure pre-date the discovery of the underlying
mechanisms demonstrating that PNH is not merely a disease of erythrocytes (5).
Pathogenesis
PNH results from the non-malignant clonal expansion of haematopoietic stem
cells that contain a somatic mutation in the gene phosphatidylinositol glycan class A
(PIGA) found on the X-chromosome (23). PIGA encodes for a glycosyl transferase
that is required in the biosynthetic pathway for the synthesis of glycosyl
phosphatidylinositol (GPI) (24). Progeny of haemopoietic stem cells containing a
PIGA mutation (erythroid, lymphoid and myeloid) harbour the same mutation leading
to a population of peripheral blood cells that are deficient in GPI-anchored proteins
(GPI-AP).
All cells have the potential to develop a somatic mutation in PIGA leading to
GPI-AP deficient cells. In fact GPI-AP deficient cells have been identified in healthy
controls but these are due to somatic mutations in a fully differentiated cell line and
cannot self-renew (25). Somatic mutations in PIGA also occur in patients with bone
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marrow failure (26). The main question is why the PIGA mutant clone should expand
preferentially compared to normal haemopoietic stem cells. A two-step hypothesis
has been suggested. The PIGA mutation itself is an essential first step in disease.
However, secondary mutation (27) or resistance to apoptosis (28) might give these
cells a survival advantage and explain in some patients why clonal selection should
occur. In the case of the latter, GPI-AP deficiency itself may be important in helping
the cell evade pro-apotoptic signals in certain circumstances whereas normal cells
may not, allowing the mutant PIGA clone to expand (29, 30).
In addition, patients have phenotypic mosaicism of PNH erythrocytes. Cells
from an individual clone may be completely deficient in GPI-AP (type III PNH
erythrocytes) or partially deficient (type II PNH erythrocytes) and exhibit
approximately 10% of GPI-AP. Cells that have normal expression of GPI-AP are
termed type I erythrocytes (20). Individuals with PNH will have erythrocytes of a
combination of the three subtypes.
Underlying haemolysis and the development of anaemia in PNH is the absence
of two GPI-anchored complement regulatory proteins CD55 and CD59 from
erythrocytes. Deficiency of these complement regulators is critical to PNH
erythrocytes being susceptible to complement-mediated attack. In general, type III
cells will undergo spontaneous lysis. Type II cells have sufficient expression of CD55
and in particular CD59 to avoid spontaneous lysis (31) though if type II cells
predominate in the circulation, brisk haemolysis may occur in the setting of a trigger
that enhances complement activation such as trauma, infection, pregnancy (20).
Haemolysis in turn leads to free haemoglobin and nitric oxide depletion that can
have consequences that extend beyond anaemia. Whilst it isn't completely clear why
individuals should have clones exhibiting different degrees of GPI-AP deficiency, it is
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clear that those patients who develop the largest population of type III erythrocytes
will have more clinically significant disease (23).
The proposed mechanisms of thrombosis in PNH are multiple and a complete
description is beyond the scope of this review. Nonetheless the absence of GPI-AP
on the platelet surface is likely to play a strong role in contributing to thrombotic risk
as reviewed by Hill et al (32).
Even though there is MAC formation upon the platelet surface due to CD59
deficiency platelet survival in PNH appears to be normal (33). Instead, both MAC
formation (34) and some downstream effects of haemolysis (35)(circulating free
haemoglobin and nitric oxide (NO) depletion) can result in platelet activation that is
associated with increased thrombotic risk (36). The absence of other GPI-AP
(including urokinase-type plasminogen receptor (37), and tissue factor pathway
inhibitor (38)) are also thought to play a potential role in the mechanisms contributing
to thrombotic risk.
Chronic kidney disease (CKD) is a consistent sequelae of PNH (39). Free
haemoglobin from haemolysis has been shown to increase renal accumulation of
haemosiderin, leading to tubulointerstitial inflammation and kidney damage (40).
Free haemoglobin also results in NO depletion that could deleteriously affect
vascular tone, particularly in the afferent arterioles of the glomerulus with a negative
effect upon glomerular filtration rate and renal blood flow (41). Other consequences
that are thought occur due to NO depletion are pulmonary hypertension,
gastrointestinal dystonia and erectile dysfunction (35).
Eculizumab for the treatment of PNH and aHUS TR-14-218R1
11
Diagnosis
In patients with PNH, laboratory tests reveal Coombs’ negative intravascular
haemolysis and raised lactate dehydrogenase (LDH). The minimal essential criteria
for diagnosing PNH (20) are using flow cytometry to determine the prevalence GPI-
AP deficient blood cells (42) and assessment of bone marrow function. GPI-AP
deficiency is measured on erythrocytes and polymorphonuclear leukocytes. Due to
haemolysis, measurement of GPI-deficiency on erythrocytes alone would
underestimate the size of the clone. The anaemia in PNH patients is contributed to
by haemolysis and the extent of any associated bone marrow failure. (20).
Symptoms and prognosis
The symptoms of PNH are predominantly constitutional (fatigue, lethargy,
malaise). Nocturnal haemoglobinuria is present in only 25% of patients. Additional
symptoms may include dysphagia, odynophagia, abdominal pain and male
impotence, typically at times of dramatic haemolysis.
PNH is a highly co-morbid condition due to the complications of anaemia (43),
thrombosis (32) and chronic kidney disease (39). Thrombotic events are common in
PNH. A thrombotic event is usually reported in 29% to 44% of PNH patients are the
major cause of mortality accounting for 40% to 67% of deaths for which the cause is
known (32). Thrombus develops at unusual sites such as visceral (hepatic vein,
mesenteric, portal, splenic, inferior vena cava) or cerebral veins; arterial thrombosis
is less common. In 19% of cases, visceral thrombi precede the diagnosis of PNH.
There is geographical variation in thrombosis rates though the exact
mechanisms are unknown. African American or Latin American PNH patients had an
increased risk of thrombosis compared with other PNH patients (44) .In a
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comparision between white American and Japanese PNH patients, a lower risk was
reported among Japanese patients (45).
Survival in the setting of thrombotic events is poor and patients with thrombosis
at presentation have a 40% survival at 4 years (32), an increased relative risk of
death of five - to 15.4 fold. Chronic kidney disease was identified in 65% of patients
in a study cohort with advanced kidney failure contributing to morbidity and mortality
of PNH (46).
Treatment of PNH
Prior to the introduction of eculizumab, the treatment was largely supportive
and reserved for symptomatic patients (20). These patients received blood
transfusion on a frequent basis. In some patients, corticosteroids ameliorated
haemolysis rapidly and their use was considered of potential use during acute
exacerbations only rather than in long-term chronic use to keep toxic effects to a
minimum (20). In the event of a thrombotic event, standard anticoagulation was used.
In cases of refractory anaemia, severe thrombotic events or severe aplastic anaemia,
bone marrow transplantation could be considered.
Eculizumab use for haemolytic anaemia in PNH
PNH erythrocytes lack CD59 and are vulnerable to MAC formation and lysis on
the cell surface leading to haemolysis. Therefore inhibition of the terminal pathway of
complement was a target for therapy and eculizumab was considered as a potential
therapeutic. The main aim of the three clinical trials (47-49) published to date of
eculizumab in PNH was to determine efficacy of eculizumab in managing the
intravascular haemolytic anaemia. Accordingly, patients were entered into the study
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if they had >10% GPI-AP deficient cells (type III), ongoing haemolysis and
transfusion requirements. Previously published trials and studies looking at the
treatment of anaemia have been summarised in table 2. Patients who received
eculizumab had ongoing albeit low transfusion requirements and much lower
haemolysis rates with LDH on average slightly above the upper limit of normal. This
observation is seen in the various single-centre studies too reflecting the off-trial
experience and use of eculizumab in the clinician’s hands (50-54) including a study
of a paediatric cohort (55).
A further observation is an increase in the size of the GPI-AP type III
erythrocyte clone due to increased survival. There is a concern that this could lead to
dramatic haemolysis in the event that eculizumab was stopped. Brodsky et al (49)
identified 19 patients out of 195 who had discontinued eculizumab following the
clinical trial setting. Withdrawal from eculizumab did not so far lead to severe
haemolysis in these patients.
Factors that predict a favourable response were studied by Dezern et al (54).
Patients who had the best response resulting complete remissions (defined as stable
and normal haemoglobin without evidence of haemolysis) had a fall in size of type III
erythrocytes. Other factors that could lead to a poorer response included concurrent
systemic inflammation and more severe underlying bone marrow failure.
Eculizumab and thrombosis in PNH
In the UK study (50), 34 thrombotic events were observed in 21 patients before
starting eculizumab. Seventeen events occurred whilst on anticoagulation supporting
the theory that anticoagulation alone does not prevent thrombosis. There were just 2
events occurring whilst on eculizumab. The thrombotic event rate before and after
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eculizumab was 5.6 vs 0.8 per 100 patient years, a statistically significant reduction.
More specifically, out of 7 patients who had a thrombosis prior to commencing
eculizumab, none have had further events whilst on eculizumab. Furthermore, in 21
patients who have stopped primary prophylactic anticoagulation since commencing
eculizumab, none have developed thrombosis.
In the extension study of the three main trials (56), eculizumab led to an 81.4%
decrease in thrombotic events in the extension study of eculizumab, a statistically
significant change. In patients who subsequently stopped anticoagulation; none
developed a further thrombotic episode. Therefore, although thrombotic events were
not an outcome measure in the studies, the data suggests that eculizumab does
reduce thrombosis in PNH patients.
Eculizumab and CKD
Data from patients in the TRIUMPH study compared renal function from those
treated with eculizumab and those with placebo. Eculizumab significantly improved
kidney function over 6 months (46). Improvement in renal function could be shown
for all 195 patients recruited into the extension study and the effect was greatest in
those patients with Chronic Kidney Disease stage 1 or 2 (milder renal impairment).
Other benefits of Eculizumab in PNH
In a study involving the patients originally enrolled in the TRIUMPH study, it as
shown that intravascular haemolysis caused a state of NO catabolism leading to
pulmonary hypertension that could be corrected using eculizumab. Dyspnoea was
improved independent of anaemia status (57). There have been individual reports
where there were improvements in gastrointestinal symptoms (58).
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Eculizumab and survival
In the extension study of 195 patients from the original clinical trials, there were
4 deaths. The Kaplan-Meier estimate of survival at 36 months was 97.6% that was
sustained out to 66 months. None of the deaths were considered related to
eculizumab treatment. (56). This survival rate is similar to the 5-year rate reported in
the single-centre retrospective analysis of 79 patients by Kelly et al (50). These
survival rates are a marked improvement when compared to historical rates of 65%
survival 5 years in patients with ongoing haemolysis (43)
Breakthrough of haemolysis
The standard maintenance dose in PNH is 900mg every 14 days and should
maintain a trough drug level of 35μg/ml, sufficient to prevent MAC formation. In 21 
out of the 195 patients in the extension study that reported breakthrough haemolysis,
shortening the interval between doses was sufficient to maintain inhibition of
haemolysis (56). Clearly monitoring for breakthrough of haemolysis is important as
part of patient monitoring. In the case of persistent breakthroughs, Hillmen et al (56)
recommend testing for human anti-human antibodies or neutralising antibodies. Two
of the patients in the long-term extension study were found to have low-positive
antibody level – in both cases there was no impact on the function of eculizumab.
Limitations of Eculizumab in PNH
The consistent finding that there was ongoing (albeit minimal) haemolysis has
led to further studies. Eculizumab has led to an increase in circulating PNH
erythrocytes. Risitano et al (59) and Hill et al (60) studied these PNH erythrocytes in
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patients treated with eculizumab and compared to non-treated PNH erythrocytes.
PNH erythrocytes treated with eculizumab had evidence of a positive direct
antiglobulin test. These cells were then examined on flow cytometry demonstrating
the presence of C3b on the cell surface. This finding was unique to Type III PNH
erythrocytes and did not occur in type II (or Type I) cells. The likely explanation for
this is that Type III PNH erythrocytes are completely deficient in CD55 therefore
unable to regulate formation of C3bBb on the cell surface. This allows ongoing
deposition of C3b through C3bBb and the alternative pathway. These erythrocytes
become heavily coated with C3b that eventually leads to removal via the reticulo-
endothelial system leading to extravascular haemolysis. This is likely an
exaggeration of an effect that was already occurring in the natural history of disease
but masked by rapid intravascular haemolysis.
Rondelli et al (61) then looked at the potential role of C3 and CR1
polymorphisms to explain why some patients were more likely to develop
extravascular haemolysis. The hypothesis was that certain polymorphisms including
that of the C3 F/S may affect the ability of C3bBb to form on GPI-AP type III cells.
They identified the potential role of the High/Low genotype in HindIII of CR1. In
eculizumab treated PNH cells, they found that the binding of C3 fragments to
erythrocytes was highest for the Low/Low genotype. This suggests that CR1 density
on the cell surface has a role in protecting against C3 binding. This was a study
limited to erythrocytes from a few patients. This and other mechanisms leading to C3
binding require further study.
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Other complement modulator treatments in PNH
Eculizumab blocks the lytic pathway and overcomes the complications of CD59
deficiency. However, the absent CD55 remains a problem in eculizumab treated
cells resulting in opsonisation of cells with C3b. This has led to several novel
potential therapeutic agents being investigated targeting C3 and the activity of the
C3 convertase. In-vitro study of potential therapeutic agents now include monoclonal
antibody against C3b (62), a mini-FH comprising the regulatory and recognition
domains of FH (63). a novel fusion protein TT30 (64), a peptide inhibitor of C3
(Cp40)(65) and aurin tricarboxylic acid (66).
Eculizumab in clinical use for PNH
Eculizumab is currently recommended in PNH patients with ongoing transfusion
requirements, thrombosis related to PNH, haemolysis related complications such as
CKD, pulmonary hypertension, and during pregnancy with concurrent haemolytic
PNH (67). PNH is a disease of chronic and ongoing haemolysis so treatment is
usually recommended lifelong. Patients with asymptomatic PNH clones should be
monitored for changes in the size of clone and for the onset of symptoms. In some
patients, clone size may spontaneously decline.
Atypical HUS
Atypical haemolytic uraemic syndrome is the prototypal disease of over-
activation of the alternative complement pathway (68). Microangiopathic haemolytic
anaemia, thrombocytopaenia and acute kidney injury are the hallmarks of haemolytic
uraemic syndrome. Renal biopsy reveals the characteristic pathological finding of
thrombotic microangiopathy (TMA). Atypical haemolytic uraemic syndrome describes
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those cases of HUS that are not caused by Shiga-toxin (Stx) resulting from certain
diarrhoeal illnesses such as Escherichia coli 0157:H7 (69).
Pathogenesis
Complement activation due to abnormalities of the complement system are the
hallmark of aHUS. Loss of function mutations in complement regulators and gain of
function mutations in complement components have been described in aHUS.
Additionally, autoantibodies to complement regulatory proteins have been identified.
A complete description of all of the genes potentially involved, the numerous
mutations and the insight gained into mechanisms of disease have been extensively
reviewed (6, 70) and are beyond the scope of this review. However, important points
are summarised below and in table 3.
Factor H is the major fluid phase regulator of complement and is characterised
by an N-terminal regulatory domain that binds to C3b and carries out its regulatory
functions of decay acceleration and co-factor activity. There is also a distinct binding
domain at the C-terminus of FH that binds to C3b and glycosaminoglycans (GAG)
(71) such as those residing upon the glomerular endothelium. Critically, many of the
mutations that have been identified in FH are in this domain suggesting the
importance of this C-terminal domain in recruiting FH to the glomerular endothelial
surface (72).
Mutations in any of FH (72, 73), FI (74) and CD46 (75) can lead to loss of
expression (type 1 mutation) or a loss of function (type 2 mutation) as measured in
serum levels or functional experiments respectively and therefore resulting in loss of
regulation of complement.
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C3 and FB are part of the activation system of complement. Important
mutations in these genes lead to over activity usually by increased formation of
C3bBb or resistance to decay acceleration (76, 77).
Autoantibodies against complement regulators have been identified in aHUS.
Most commonly they are directed against an epitope mapped to the C-terminus of
FH (78). These are usually shown to block the ability of FH to bind to C3b or GAGs
and therefore inhibit complement regulation at the glomerular endothelium. Some
antibodies bind to other regions or FH and the significance of these in disease are
less certain (79). Antibodies have been described against FI in a few cases (80). The
functional significance of these has not been confirmed.
Single nucleotide polymorphisms (SNPs) have been described in FH that
associate with a 2-4-fold increased risk of aHUS. A haplotype in FH (FH-H3; tgtgt)
contains the SNP V62I (81, 82). Functional analysis has shown the V62 risk variant
has a small decreased in cofactor activity compared to I62. A haplotype block in
CD46 (CD46ggaac) comprises two SNP in the promoter region that associates with
a 2 to 3-fold increased risk of aHUS (82). The functional effect of this is less clear.
Penetrance of disease has been reported at around 50% for individuals
carrying a single genetic mutation (83) suggesting that additional disease risk
modifiers are important. In fact, 3.4% of patients have one or more mutation, with
increased penetrance per extra mutation (84). Thus patients have an increased risk
of disease with inheritance of mutations and risk haplotypes. Together, these still do
not explain why some patients develop disease until later in life. This is best
explained by the need for an environmental trigger such as infection (non-Stx), drugs
and pregnancy (6).
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Diagnosis
Patients with aHUS have low haemoglobin, appearance of schistocytes on
blood film, raised LDH, low platelets and raised creatinine. It is important to exclude
Stx-HUS by testing for E-coli 0157 on stool culture and PCR. ADAMTS13 levels are
also measured to exclude thrombotic thrombocytopaenia (TTP) to allow early
appropriate therapy. Genetic and immunological testing for complement
abnormalities should be performed. DNA should be tested for mutations in C3, FB,
FH, FI, CD46 and copy number variation. Most centres now also suggest testing for
mutations in DGKε, encoding a protein not in the complement system. Serum should 
be sent for C3, C4, FH and FI and complement antibody screening prior to initiation
of plasma exchange. FACS analysis of peripheral blood mononuclear cells for CD46
should be performed.
It should be noted that Selier-leclrec et al (85) describe some patients within an
aHUS cohort that presented with haematuria and proteinuria without renal failure or
‘uraemia’. The possibility of an underlying complement defect should be considered
if there is evidence of a TMA, even without a raised creatinine, potentially in the
setting of extra-renal manifestations (see below).
Symptoms and prognosis
Patients with aHUS typically present with symptoms of lethargy, malaise,
oedema consistent with the onset of acute kidney injury. They may report prior
infective symptoms reflective of a trigger.
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There are extra-renal manifestations that have been reported in 10-20% of
patients. Most commonly (10%) these are neurological and range from mild irritability
to coma (6). Other rare symptoms have been reported in individual case reports and
are summarised in (6). The extent to whether these extra-renal manifestations are
due to TMA is less clear. In a study of patients at autopsy, patients historically
diagnosed with HUS had evidence of fibrin-rich thrombus in brain, heart and
pancreas tissue suggesting that these are extra-renal manifestations of HUS.
However, these were not distinguished from TTP by ADAMTS13 activity or analysis
of the complement system (86).
Historically, aHUS was a progressive disease with poor prognosis with 48% of
children and 67% of adults dying or reaching end stage renal failure within 5 years
(87). Patients with a mutation in MCP generally had a better prognosis, those with
mutations in FH, FI C3 and FB had similarly poorer prognosis (87). In those patients
that receive kidney transplants, disease recurrence rates leading to graft failure are
60-70% (88). Again, patients with mutations in CD46 have the lowest rates of
recurrence; mutations in the other complement genes predict the highest recurrence
rates.
Treatment of aHUS
Prior to the introduction of eculizumab the gold standard for therapy was
plasma exchange (PEX). Replacement of ineffective or deficient regulatory proteins
or the removal of neutralising antibodies and hyperfunctional complement proteins
made PEX the logical choice for therapy. Once haemolysis was controlled, PEX
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could be withdrawn. Despite this, the prognosis in such patients remained poor and
progression to end stage renal failure was common with rates as stated earlier.
Eculizumab use in aHUS
Pickering et al (81) generated a transgenic mouse lacking the C-terminal
recognition domains of FH leading to these mice spontaneously developing aHUS.
When crossed with a C5 deficient mouse (89), these mice did not develop aHUS
suggesting the importance of a role downstream of C3b generation. Therefore,
regardless of trigger and underlying genetic mutation, there is evidence that
complement activation converges on the terminal pathway suggesting the potential
role of eculizumab in aHUS.
The first reports describing the use of eculizumab in aHUS were published in
2009 (90, 91) describing the effect of eculizumab in achieving remission from
thrombotic microangiopathy in patients with aHUS in native kidney and also in
recurrent disease in a renal transplant. This and other initial reports are summarised
in Wong et al (92). Most were successful in achieving remission but of course
subject to publication bias.
Following these initial studies were the phase 2 trials of eculizumab (93)
summarised in table 4. Two prospective open-label single arms studies were set up
and enrolled patients that either 1) had progressive haemolysis despite PEX (C08-
002) or 2) had control of haemolysis but remained dependent upon ongoing PEX
therapy (C00-003). Seventeen patients were entered into C08-002 and twenty into
C08-003. Patients with aHUS affecting native kidney or transplanted kidney were
included in both. Subsequently results from a single centre study of off label use of
eculizumab in 19 patients (native kidneys) have also been published (94).
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The result from these studies show that eculizumab quickly established
remission of TMA resulting in normalisation of platelet count, haemoglobin with
improvement in renal function (including some who required dialysis). In the two
phase 2 trials, this was observed in the first 26 weeks of the initial trial and was
sustained during the first extension phase (93). In the off-label study, all patients had
disease remission during the follow up period of 4-22 months (94).
This was confirmed in a paediatric study of 15 patients (C09-001) (95) of whom
14 were treated for aHUS in the native kidney. The remaining patient had treatment
of recurrent disease in a kidney transplant. Again, 80% achieved a TMA-free status
with no patients proceeding to needing dialysis.
Patients who have required dialysis for several months have benefited from
eculizumab recovering to independence from dialysis (96). The duration that
eculizumab should be continued for once a patient requires dialysis to allow potential
recovery is less clear.
Eculizumab as pre-emptive treatment in renal transplantation
Another cohort that appears to benefit from eculizumab is the group of patients
who have been classified as high risk of disease recurrence in a renal transplant due
to mutations. Rather than wait until recurrence before instigating treatment, patients
were given eculizumab at the time of transplantation as pre-emptive therapy.
Published reports of this use in 10 patients were reviewed by Wong et al (92). All
had mutations that predict a high risk of recurrence and 2 had had previous
recurrence in transplant. All patients remained free from disease recurrence at latest
follow up of up to 2 years, though one had graft loss due to arterial thrombosis.
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Discontinuation of Eculizumab in patients in remission
Within a cohort of French patients that had been successfully treated with
eculizumab leading to resolution of TMA and recovery from dialysis requirement, 10
patients had chosen to discontinue eculizumab (97). These patients were monitored
for urinary abnormalities using urine dipstick. Amongst these patients, all had FH
mutations and 8 had previously required dialysis. They had received eculizumab for
a median of 5.6 months (range 0.4-14.2). Out of 5 patients that developed
haematuria, only 3 had clinically significant disease showing other evidence of
haemolysis. These relapses occurred within 6 weeks of discontinuation of
eculizumab with associated elevation in creatinine. All 3 patients responded rapidly
to restarting eculizumab with resolution of haemolysis and kidney injury. The total
(cumulative) time off eculizumab for the entire cohort was 95 months (median, 9.3;
range, 0.9-22.7) months. The other 7 patients remain in remission off eculizumab.
Limitations of Eculizumab in aHUS
In addition to abnormalities of the complement pathway, other pathways of
disease are being identified in aHUS cohorts. Most notable is the finding of
homozygous or compound heterozygote mutations in diacylglycerol kinase ε (DGKε) 
in young affected patients (98, 99). DGKε encodes a phosphorylase and is likely to
affect the prothombotic pathway. There is no known association with the
complement pathway and therefore eculizumab is unlikely to be effective in this
cohort. This was reported in the study by Lemaire et al (99). It is plausible that other
non-complement pathways exist in aHUS.
For this reason, George and Nester (100) avoid the term aHUS altogether and
suggest the term complement-mediated HUS as well as coagulation-mediated HUS.
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The limitations that we describe are probably due to the usefulness of the historical
term aHUS rather than that of Eculizumab itself. Use of the term complement-
mediated HUS may represent a future direction in classification though further
discussion of this is beyond the scope of this review.
Clinical use of Eculizumab in aHUS
Eculizumab is recommended for use in patients with aHUS once stool or blood
samples have ruled out Stx-HUS and ADAMTS13 levels >10% have been confirmed
to exclude TTP.. Plasma exchange may remain the initial treatment until this has
been achieved. In paediatric patients where PEX can be difficult to administrate,
eculizumab may be used as a first line therapy. Commencement of eculizumab need
not wait for confirmation of a genetic or acquired complement abnormality, though
the results of these tests may determine the duration of treatment (see below)
Patients that undergo transplantation with high risk mutations (e.g. FH, C3 and
FB) have unavoidable ischaemia–reperfusion injury induced complement activation
making pre-emptive eculizumab the treatment of choice in our opinion.
Family members with a mutation have a low penetrance rate but disease onset
may occur when exposed to a triggering stimulus. A strategy of careful monitoring is
recommended for these patients.
The decision of when to stop eculizumab is more difficult to determine in terms
of the evidence available. Ultimately, the aim is to balance the risk of eculizumab
(see side-effects) against effective treatment and prevention of recurrence of TMA
and the organ-specific damage associated with it. In individuals where TMA has
been controlled but renal function has not recovered eculizumab has usually been
discontinued. There are, however, rare reports of severe extra-renal manifestations
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such as cerebral artery stenoses which have been attributed to ongoing complement
activation (101). The experience is currently too limited to recommend routine
ongoing treatment with eculizumab in individuals on long term dialysis.
Ardinisso et al describe a small group of patients that discontinued eculizumab
despite initial concerns that they would be at high risk of recurrence (97). This seems
to have been well-tolerated with only 3 patients developing recurrent disease.
However, knowing precisely which sub-group of patients would tolerate cessation,
and at what time point into their treatment is hard to be certain. Further study is
required.
Where genetic analysis reveals DGKε mutation, it is unlikely that complement
inhibition will have affected the natural history of disease. In fact, there is at least one
report of a patient that had recurrent disease whilst receiving eculizumab.
Eculizumab should be stopped in these patients (99).
Pregnancy and Eculizumab in PNH and aHUS
Pregnancy is associated with poor outcomes in both PNH (102, 103) and aHUS
(104). It is rarely reported with ~100 cases and ~20 respectively in the reported
literature. Prior to the availability of eculizumab, PNH in pregnancy was more difficult
to manage than usual due to increased haemolysis, transfusion requirements,
tendency to thrombosis and ultimately increased maternal and foetal mortality (103).
In aHUS triggered by pregnancy, the usual poor prognosis associated with aHUS is
not diminished (104).
The introduction of eculizumab may be of particular benefit to this cohort of
patients. The use of eculizumab in pregnancy in either disease is limited to small
numbers. Hillmen et al report 7 patients who received eculizumab during pregnancy
Eculizumab for the treatment of PNH and aHUS TR-14-218R1
27
(102). Of these, 3 remained on eculizumab at the time of delivery with successful
outcomes. In aHUS, most patients develop aHUS in the post-partum period (104)
reducing the concerns regarding safety during pregnancy. In the one case report that
describes eculizumab during pregnancy and aHUS, haemolysis was controlled and
there was improvement in renal function(105). There was no apparent complication.
Safety of using Eculizumab
The most extensive use of eculizumab is in patients with PNH. Hillmen et al
(2013) reported the safety profile in their 195 patients that had received eculizumab
during the open-label extension study (56). Eculizumab was well tolerated during the
study. The most frequent adverse events (AE) were headache, nasopharyngitis and
upper respiratory tract infection, reported in greater than 40% of patients. The
majority of AE (91.3%) were mild to moderate in severity. Most of the serious AE
were symptoms that are seen in PNH. These were haemolysis, abdominal pain and
anaemia and were seen in 38.5% of patients. Only 5 patients discontinued
eculizumab due to non-fatal AE. There was no comparator placebo arm in the
extension study, but the investigators did compare the number of AE in the last 26
weeks of the study to the first 26 and found that the number of patients with 1 or
more AE was significantly lower in the last 26 weeks suggesting there was no
cumulative toxicity. Two patients had meningococcal infection and recovered
following anti-microbial treatment. Though both had been vaccinated, neither had
received vaccine for the strain that they actually developed.
Eculizumab was similarly well tolerated in the aHUS studies. Headache and
upper respiratory tract infections were the most commonly reported in the adult
phase 2 study (93). Additionally, 27 patients out of 37 had a serious AE, but all of
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those that were possibly or probably associated with eculizumab resolved without
cessation of treatment. There were no new serious AE after the initial 26 weeks of
treatment. No patients developed meningococcal infection. All had received
prophylactic anti-microbial treatment in addition to vaccination.
The use of eculizumab in the paediatric setting is more extensive in aHUS
patients compared to PNH. In the paediatric study of aHUS patients, AE were
similarly tolerated as reported in the adult studies. There were 2 patient deaths
though they were not related to eculizumab (106). In the paediatric patients with
PNH, there were no serious adverse events attributed to eculizumab.
Deposition of anti-C5 antibody on the glomerulus
In 3 patients who received eculizumab for complement-mediated glomerular
disease, there was de-novo deposition of IgGκ in the glomerular tissue demonstrated 
on renal biopsy (107). Staining of the γ-heavy chain showed IgG2 and IgG4 
subclasses consistent with deposition of eculizumab. The longer term effects of this
interaction are not known.
Polymorphisms in C5 and resistance to Eculizumab
Certain individuals (11 out of 345 patients treated with eculizumab) in a
Japanese PNH population did not respond to eculizumab despite adequate serum
levels (108). In vitro assays of serum from these non-responders demonstrated an
inability of eculizumab to prevent haemolysis. When an antibody against a different
epitope on C5 was used, haemolysis was blocked. Genetic analysis revealed a SNP
in C5 (p.R885H) in all non-responders (108). This SNP was present in around 3.2%
of patients in this cohort, similar to the prevalence of 3.5% in the general Japanese
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population. A further patient from Argentina (but also of Asian descent) presented
similarly and had a mutation affecting the same amino acid (p.R885C) (108). Non-
responders to eculizumab should have genetic screening for this SNP and
alternative treatment strategies considered.
Cost of Eculizumab
Eculizumab is one of the more expensive drugs in use currently (109). The cost
of eculizumab may alone prohibit its use in routine clinical practice. At the time of
writing, National Institute for Clinical Excellence in the United Kingdom accepts the
effectiveness of the drug (106) but cannot justify its use even in the small number of
affected patients due to its expense.
Summary
Eculizumab is a first-in-class complement inhibitor developed to target the
cleavage of C5 and therefore preventing the release of C5a and formation of MAC. It
has been shown to be effective and safe in the treatment of both PNH and aHUS.
Eculizumab exemplifies the clear benefits of targeted inhibition of the complement
system. It is now being used in clinical services for both diseases and guidelines for
use continue to evolve especially for aHUS in determining the likely duration of
treatment.
However, eculizumab only inhibits the downstream effects of complement
activation. Upstream of the site of action of eculizumab, there is ongoing
complement activation. This results in the opsonisation of PNH erythrocytes leading
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to uptake of these cells by the reticular endothelial system and extravascular
haemolysis. In aHUS, eculizumab is not effective in patients who have mutations in
genes in non-complement pathways such as DGKε. In PNH and aHUS, eculizumab
is not effective in patients who carry a polymorphism in C5 affecting the epitope for
eculizumab binding. Further studies will be required to determine whether
eculizumab remains the optimal treatment for these two diseases.
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Table 1
Complement
regulator
Function Clinical association Effect of mutation
Disease Mutation type
Factor H, FH Decay of C3 convertase
and co-factor activity for
FI
aHUS (72) FH, Germline Loss of FH expression or
function of circulating proteinMPGN (110)
AMD (111)
Factor I, FI Proteolytic cleavage of
C3b to iC3b and C3dg in
the presence of co-
factors
aHUS (74) FI, Germline Loss of FI expression or function
of circulating proteinAMD (112)
Membrane co-factor,
MCP, CD46
Co-factor activity for FI
and C4-binding protein
aHUS (75) CD46, Germline Loss of CD46 expression or
function of cell surface
Decay accelerating
factor, DAF, CD55
Decay of C3 convertase PNH (23) PIGA, Somatic in
haemopoietic stem
cells
GPI-AP deficiency on surface of
haemopoietic stem cell progeny
Inab phenotype (113) CD55,Germline Loss of expression of CD55 on
cell surface
CD59 Inhibition of MAC
formation
PNH (23) PIGA, Somatic in
haemopoietic stem
cells
GPI-AP deficiency on surface of
haemopoietic stem cell progeny
CD59 deficiency (114) CD59, Germline Loss of expression of CD59 on
cell surface
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Table 2
Study Type of study Number of
patients
Duration of
study in weeks
(Range)
Effect of Eculizumab on Thrombotic
events during
study
Other improvements
in outcome
Transfusion
requirements
LDH Proportion of Type
3 PNH
erythrocytes
Phase 2 pilot (47)
and extension (16)
Single-arm open
label and extension
study
11 64 ↓ ↓ ↑ 0 QOL, 
haemoglobinuria
TRIUMPH
Phase 3 (48)
Double blind RCT
with placebo
87 (43 on
Eculizumab)
26 ↓ ↓ ↑ 0 QOL 
SHEPHERD (49) Single arm open
label
97 52 ↓ ↓ ↑ 2 QOL 
UK (50) Retrospective Study 79 39 (1-98) ↓ ↓ N/A 1 Thrombotic events 
Japan (52) and
extension (53)
Single-arm open
label and extension
study
29 156 ↓ ↓ ↑ 0 QOL and CKD 
US (54) Retrospective study 30 24 (6-80) ↓ ↓ ↑ 1  
Phase 1/2
Paediatrica (55)
Single-arm open
label
7 12 Remained
independent
↓ Stable 0 QOL 
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Table 3
Complement
abnormality
Frequency of
aHUS patients
Effect of mutation on function
FH 25% Majority are C-terminal mutations leading to loss of binding to GAGs
on glomerular endothelial surface; Others are N-terminal mutations
leading to loss of fluid-phase complement regulation
FI 5-10% Some cause loss of co-factor activity
CD46 10% Affects binding of the extracellular domains to C3b resulting in loss of
co-factor activity
C3 2-10% C3 convertase that is more readily formed or are more resistant to
decay acceleration
FB Rare C3 convertase that is more readily formed or are more resistant to
decay acceleration
Auto-antibody to
FH
4-14% (adult),
25% (paediatric)
Binds to epitopes on C-terminal of FH leading to loss of complement
regulation. Other binding sites have been identified though function
less certain
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Table 4
Study Type of
Study
Number
of
patients
Duration aHUS in
native
kidney
(number of
patients)
aHUS in
transplanted
kidney
(number of
patients)
Previous
plasma
exchange
(number of
patients)
Patients in
whom platelet
count
normalised
(%)
Patients
achieving
TMA free
statusa
(%)
Improvement of CKD
stage or
eGFR>15ml/min
(percentage of
patients)
C08-002
(93)
Prospective 17 26 weeks 10 7 17 82 88 59b
C08-003
(93)
Prospective 20 26 weeks 12 8 20 90 80c 35d
C09-001
(95)
Retrospective 15 N/A 14e 1 N/A 93 80% 53
Fakhouri
et al (94)
Retrospective 19 4-
22months
19 0 16 100 100% 75f
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Figures and Tables
Figure 1. The complement system. Activation of complement C3 to form C3b can
occur via the three pathways, classical (CP), alternative (AP) and lectin (AP). There
is amplification of C3b by formation of the C3 convertase (C3bBb) in a positive
feedback loop. C5 convertases (C3bC3bBb) then form and cleave C5 into C5a and
C5b. C5b then enters the terminal pathway to bind C6, C7, C8 and finally C9 to form
the membrane attack complex (MAC, C5b-9). The sites of action of complement
regulators (FH, FI, CD46, CD55, CR1 and CD59) or inhibitor (Eculizumab) are
indicated by the dotted arrow. The specific function of the complement regulators is
described in tables 1 and 3. In PNH, CD59 deficiency on the surface of PNH
erythrocytes leaves the erythrocyte vulnerable to MAC formation and lysis. In aHUS,
mutations FH, FI and CD46 lead to loss of regulation of C3b activation and
amplification. Conversely mutations in C3 and FB lead to hyperfunctioning
complement components leading to over-activity of C3 convertase. Eculizumab is a
monoclonal antibody that binds to C5 and blocks cleavage of C5 and therefore
prevents MAC formation.
Table 1. Complement regulators, function and disease association. MAC -
membrane attack complex; aHUS – atypical haemolytic uraemic syndrome; MPGN –
membranoproliferative glomerulonephritis; AMD – age-related macular degeneration;
PNH – paroxysmal nocturnal haemoglobinuria; PIG-A - phosphatidylinositol glycan
class A; GPI-AP - glycosyl phosphatidylinositol anchored proteins
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Table 2 Studies of Eculizumab for the treatment of haemolytic anaemia in
paroxysmal nocturnal haemoglobinuria (PNH). In all studies, the dose of
Eculizumab was 600mg weekly (x4) then 900mg (x1) then 900mg fortnightly. a All
patients weighed >30kg and were dosed as per the standard regime. LDH – lactate
dehydrogenase; QOL – quality of life; RCT – randomised controlled trial; N/A – not
available; CKD – chronic kidney disease
Table 3. Complement abnormalities in aHUS, frequency and functional
significance. FH – Factor H; FI – Factor I; FB – Factor B; GAG –
glycosaminoglycans
Table 4 Studies of Eculizumab for the treatment of atypical haemolytic uraemic
syndrome (aHUS) . In the adult studies, the dose of Eculizumab 900mg weekly (x4),
1200 mg (x1) then 1200mg fortnightly. Children under 40kg receive a weight-based
dose (95). adefined as ≥12 weeks of stable platelet count, no plasma exchange or 
infusion and no new dialysis. b increased to 65% at 64 weeks. c increased to 85% at
62 weeks. d increased to 45% at 62 weeks. eassumed to be 14 patients. fpercentage
of patients that became independent of dialysis at 3 months. N/A – not available;
TMA – thrombotic microangiopathy; CKD – chronic kidney disease; eGFR –
estimated glomerular filtration rate

